There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Viking Therapeutics (VKTX) and Verastem (VSTM) with bullish sentiments.
Viking Therapeutics (VKTX)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Viking Therapeutics today and set a price target of $31. The company’s shares closed yesterday at $14.04.
Pantginis said:
“Valuation and risks to price target achievement. We reiterate our Buy rating and $31 price target. Our peak sales estimates for VK2806 and VK5211 are based on our U.S. projections, and believe overall that peak sales could be conservative because of the size of the addressable markets, the continuing unmet medical need, and no projections for ex-U.S. sales currently. Our price target is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile.”
According to TipRanks.com, Pantginis ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -15.5% and a 28.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Checkpoint Therapeutics Inc, and Strata Skin Sciences Inc.
Viking Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $32.50.
See today’s analyst top recommended stocks >>
Verastem (VSTM)
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Verastem today and set a price target of $15. The company’s shares closed yesterday at $5.85.
According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of 2.5% and a 35.9% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Trillium Therapeutics.
Verastem has an analyst consensus of Strong Buy, with a price target consensus of $15.25, implying a 160.7% upside from current levels. In a report released yesterday, Oppenheimer also assigned a Buy rating to the stock with a $15 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VSTM:
